OR

356.35

+1.87%↑

B.US

42.16

+3.77%↑

ASM

673.2

+5.39%↑

IAG.ES

4.25

+5.72%↑

SY1

74.34

+1.59%↑

OR

356.35

+1.87%↑

B.US

42.16

+3.77%↑

ASM

673.2

+5.39%↑

IAG.ES

4.25

+5.72%↑

SY1

74.34

+1.59%↑

OR

356.35

+1.87%↑

B.US

42.16

+3.77%↑

ASM

673.2

+5.39%↑

IAG.ES

4.25

+5.72%↑

SY1

74.34

+1.59%↑

OR

356.35

+1.87%↑

B.US

42.16

+3.77%↑

ASM

673.2

+5.39%↑

IAG.ES

4.25

+5.72%↑

SY1

74.34

+1.59%↑

OR

356.35

+1.87%↑

B.US

42.16

+3.77%↑

ASM

673.2

+5.39%↑

IAG.ES

4.25

+5.72%↑

SY1

74.34

+1.59%↑

Search

UPM-Kymmene Oyj

Closed

27.01 1.01

Overview

Share price change

24h

Current

Min

26.74

Max

27.22

Key metrics

By Trading Economics

Income

241M

257M

Sales

14M

2.3B

P/E

Sector Avg

28.791

32.671

EPS

0.57

Dividend yield

5.79

Profit margin

11.116

Employees

14,624

EBITDA

435M

614M

Dividends

By Dow Jones

Dividend yield

Sector Avg

5.79%

3.04%

Next Earnings

29 kwi 2026

Market Stats

By TradingEconomics

Market Cap

1.4B

14B

Previous open

26

Previous close

27.01

UPM-Kymmene Oyj Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 mar 2026, 23:31 UTC

Hot Stocks

Stocks to Watch: Nike, RH, NCino

31 mar 2026, 22:35 UTC

Earnings

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 kwi 2026, 00:00 UTC

Acquisitions, Mergers, Takeovers

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mar 2026, 23:50 UTC

Acquisitions, Mergers, Takeovers

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mar 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mar 2026, 23:33 UTC

Market Talk
Major News Events

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mar 2026, 23:21 UTC

Earnings

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mar 2026, 23:14 UTC

Market Talk
Earnings

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mar 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss Widens >000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mar 2026, 22:36 UTC

Earnings

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mar 2026, 21:46 UTC

Acquisitions, Mergers, Takeovers

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mar 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mar 2026, 21:35 UTC

Earnings

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Earnings

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mar 2026, 21:35 UTC

Earnings

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mar 2026, 21:33 UTC

Acquisitions, Mergers, Takeovers

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mar 2026, 21:33 UTC

Earnings

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mar 2026, 21:32 UTC

Earnings

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mar 2026, 21:28 UTC

Earnings

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mar 2026, 21:26 UTC

Earnings

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mar 2026, 21:25 UTC

Earnings

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mar 2026, 21:24 UTC

Market Talk
Earnings

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mar 2026, 21:22 UTC

Earnings

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mar 2026, 21:22 UTC

Earnings

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mar 2026, 21:21 UTC

Earnings

Nike's Digital Channel Still Too Promotional, CFO Says

31 mar 2026, 21:20 UTC

Earnings

Nike CEO: Converse Remains Important to Portfolio

Peer Comparison

Price change

UPM-Kymmene Oyj Forecast

Financials

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About UPM-Kymmene Oyj

UPM-Kymmene Oyj, together with its subsidiaries, engages in the forest-based bioindustry in Europe, North America, Asia, and internationally. It operates through UPM Fibres, UPM Energy, UPM Raflatac, UPM Specialty Papers, UPM Communication Papers, UPM Plywood, and Other Operations segments. The company provides softwood, birch, and eucalyptus pulp for tissue, specialty, and graphic papers and packaging; sawn timber for joinery, packaging, furniture, planning, and construction industries; and wood-based renewable diesel and renewable naphtha for transport and petrochemical industry. It is also involved in the generation of electricity through hydro, thermal, and nuclear power plants. In addition, the company offers self-adhesive label materials for branding and promotion, information, and functional labeling in the food, beverage, personal care, pharmaceutical, and logistics segments; and specialty packaging materials, such as label papers, release liners, office papers, and flexible packaging for labeling, packing, commercial siliconizing, and printing, as well as graphic papers for advertising, publishing, and home and office use. Further, it provides plywood and veneer products for construction, vehicle flooring, liquefied natural gas shipbuilding, and parquet manufacturing, as well as for other industrial applications; wood and wood-based biomass, and forestry services for forest investors and owners; wood-based biomedical products, such as nano-fibrillar cellulose for clinical and life science applications; wood-based lignin products for industrial use; and UPM ProFi decking products and UPM formi granules. Additionally, the company offers financial portfolio management services. UPM-Kymmene Oyj was founded in 1871 and is headquartered in Helsinki, Finland.
help-icon Live chat